What is the evidence behind using Doxycycline 500mg IV for liver sclerotherapy?

What is the evidence behind using Doxycycline 500mg IV for liver sclerotherapy?

Comment by InpharmD Researcher

Available evidence for doxycycline as a sclerosant for hepatic cysts is sparse. One dated case report described successful percutaneous drainage and sclerosis using intracystic doxycycline (1,500 mg in 300 mL of normal saline); however, the anecdotal nature of the evidence prevents conclusions regarding efficacy or optimal dosing. Additional evidence comes from another dated investigation in which doxycycline was one of several sclerosants used, but outcomes were not reported separately for doxycycline. Although tangentially related, pharmacokinetic data suggest limited doxycycline penetration into hepatic cysts following systemic administration; however, the clinical applicability of these findings to intracystic instillation is unclear. Minocycline, another tetracycline derivative, has been evaluated separately in a small retrospective series with intracystic administration, though these findings cannot be directly extrapolated to doxycycline.

Background

The 2024 American College of Gastroenterology (ACG) guideline for focal liver lesions states that aspiration sclerotherapy for symptomatic hepatic cysts may be performed using 100% ethanol, tetracycline, or other sclerosants, with maximal benefit taking up to 6 months. The guideline also recommends against cyst aspiration alone due to high recurrence rates. Doxycycline is not specifically mentioned as a sclerosant in the guideline. [1]

A 2012 review article highlights that percutaneous sclerotherapy of simple hepatic cysts has been performed using ethanol, tetracycline, minocycline, and doxycycline. The review references only one dated study involving doxycycline (see Table 1), which evaluated percutaneous drainage and sclerosis in 20 patients with 24 symptomatic hepatic cysts. Sclerosants used included alcohol, tetracycline, doxycycline (dose not specified), or combinations (alcohol and doxycycline or tetracycline). Overall, 21 of 24 cysts were successfully treated; however, only one patient received doxycycline alone (not in combination), and outcomes were not reported separately, limiting assessment of its individual efficacy. [2], [3]

Literature Review

A search of the published medical literature revealed 4 studies investigating the researchable question:

What is the evidence behind using Doxycycline 500mg IV for liver sclerotherapy?

Level of evidence

C - Multiple studies with limitations or conflicting results Read more→

Please see Tables 1-4 for your response.

Symptomatic Hepatic Cysts: Percutaneous Drainage and Sclerosis
Design	Retrospective study N= 20
Objective	To evaluate the authors' experience with treatment of symptomatic hepatic cysts by means of percutaneous catheterization and sclerosis
Study Groups	All patients (n= 20)
Inclusion Criteria	Patients with symptomatic hepatic cysts, including those with polycystic disease and solitary cysts
Exclusion Criteria	Patients who had undergone surgery for hepatic cyst disease
Methods	Percutaneous catheter drainage and sclerosis using alcohol, tetracycline, doxycycline, or a combination. Sclerosis was performed after complete drainage of the cyst fluid. The procedure was guided by ultrasound or CT, and the sclerosant was left in the cyst for 20-30 minutes with the patient being repositioned to ensure coating of the cyst walls,
Duration	9-year period
Outcome Measures	Successful treatment of hepatic cysts
Baseline Characteristics		All patients (n= 20)
	Gender - Male	5
	Gender - Female	15
	Age range, years	25 to 87
	Polycystic disease	10
	Solitary cysts	10
	Several types of sclerosants were used. These included alcohol alone (n= 14), tetracycline alone (n= 4), doxycycline alone (n= 1), or a combination of alcohol and doxycycline or tetracycline (n= 5)
Results		Number of cysts
	Successfully treated	21 of 24
	Unsuccessful treatment	3 of 24
Adverse Events	Complications included pleural effusion in two patients and secondary infection in one patient. Pain from alcohol infusion was common but often relieved by lidocaine.
Study Author Conclusions	Percutaneous catheter drainage with sclerosis is an effective method of therapy for symptomatic hepatic cysts; careful patient selection is essential for proper therapy.
Critique	The study provides valuable insights into the treatment of symptomatic hepatic cysts using percutaneous drainage and sclerosis. However, the retrospective nature and small sample size may limit the generalizability of the findings. Importantly, only one patient received doxycycline alone, and outcomes were not reported separately, limiting assessment of its individual efficacy.

Table 1 References:
[4] vanSonnenberg E, Wroblicka JT, D'Agostino HB, et al. Symptomatic hepatic cysts: percutaneous drainage and sclerosis. Radiology. 1994;190(2):387-392. doi:10.1148/radiology.190.2.8284385

Long-term results of multiple minocycline hydrochloride injections for the treatment of symptomatic solitary hepatic cyst
Design	Retrospective study N= 9
Objective	To present the long-term results of multiple minocycline hydrochloride injections for the treatment of symptomatic solitary hepatic cyst
Study Groups	All patients (n= 9)
Inclusion Criteria	Patients with symptomatic solitary hepatic cysts, aged between 41–72 years, with upper abdominal discomfort or pain, and normal initial laboratory tests except for one patient with mild liver dysfunction
Exclusion Criteria	Patients with hemorrhagic diathesis, echinococcal cyst, protrusion of the hepatic vein into the cyst, communication with the biliary tree, or extravasation into the peritoneal cavity
Methods	Insertion of an 8 or 9-French catheter into the cyst, followed by injection of 200 mg of minocycline in 10 mL saline, and flushing with 10 mL saline. The catheter was clamped for 30 minutes. Minocycline injection was performed daily for 7-8 days
Duration	Follow-up: 42–153 months (mean 85 months)
Outcome Measures	Cyst regression without recurrence
Baseline Characteristics		All patients (n= 9)
	Age, mean years	58.2
	Sex - Female	7
	Sex - Male	2
	Cyst diameter, mean cm	14.1
Results		All patients (n= 9)
	Cyst regression without recurrence	9 (100%)
	Pain or discomfort resolution	9 (100%)
Adverse Events	One patient experienced moderate right subscapular pain immediately after injection, and one patient experienced pain at the catheter insertion site.
Study Author Conclusions	Multiple injections of minocycline are safe and definitive treatments for symptomatic solitary hepatic cysts.
Critique	The study demonstrates the effectiveness of multiple minocycline injections in treating hepatic cysts with no recurrence. However, the small sample size and lack of a control group limit the generalizability of the findings. Additionally, the retrospective nature of the study may introduce bias.

Table 2 References:
[5] Yoshida H, Onda M, Tajiri T, et al. Long-term results of multiple minocycline hydrochloride injections for the treatment of symptomatic solitary hepatic cyst. J Gastroenterol Hepatol. 2003;18(5):595-598. doi:10.1046/j.1440-1746.2003.03025.x

Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial
Design	Prospective, randomized single-dose pharmacokinetic (PK) study N= 20
Objective	To investigate tissue penetration of four antibiotics in non-infected liver cysts and explore influencing factors
Study Groups	Group 1: ciprofloxacin and piperacillin/tazobactam (n= 11) Group 2: co-trimoxazole and doxycycline (n= 10)
Inclusion Criteria	Adult patients with symptomatic liver cyst(s) without current cyst infection, suitable for percutaneous aspiration sclerotherapy
Exclusion Criteria	Allergy or contraindications for study drug use, severe renal impairment (eGFR < 30 mL/min/1.73 m2), use of antibiotics in the 7 days before aspiration sclerotherapy
Methods	Group 1 received IV ciprofloxacin (200 mg) and piperacillin/tazobactam (4000/500 mg). Group 2 received IV trimethoprim/sulfamethoxazole (160/800 mg) and doxycycline (200 mg). Cyst fluid and blood samples were collected and analyzed using LC-MS/MS
Duration	Patients were included between 2019 and 2020. Analysis completed in 2023
Outcome Measures	Liver cyst penetration (cyst-fluid-to-plasma concentration ratio)
Baseline Characteristics		Total group (n = 20; cysts = 21)	Group 1: ciprofloxacin and piperacillin/tazobactam (n = 10; cysts = 11)	Group 2: co-trimoxazole and doxycycline (n = 10; cysts = 10)
	Age, years	61 (55–68)	59 (44–65)	63 (55–72)
	Female	18 (90%)	9 (90%)	9 (90%)
	Aetiology Solitary cyst Polycystic liver ADPLD Polycystic liver ADPKD	11 (55%) 7 (35%) 2 (10%)	7 (70%) 2 (20%) 1 (10%)	4 (40%) 5 (50%) 1 (10%)
	Length, m	1.69 (1.6–1.8)	1.71 (1.6–1.8)	1.66 (1.62–1.80)
	Weight, kg	70.9 (59.3–95.4)	74.0 (57.8–113.1)	66.4 (59.0–80.2)
	BMI, kg/m²	23.7 (20.7–30.0)	24.5 (20.1–35.7)	23.7 (21.8–27.7)
	Renal function (eGFR) Normal (≥90) Mild (60–89) Moderate (30–59)	9 (45%) 10 (50%) 1 (5%)	6 (60%) 3 (30%) 1 (10%)	3 (30%) 7 (70%) 0 (0%)
	eGFR, mL/min/1.73 m²	88 (69 – >90)	>90 (81 – >90)	80 (64 – >90)
	Cyst diameter, cm	123 (91–145)	113 (98–134)	131 (87–174)
	Aspirated cyst volume, mL	700 (375–1200)	700 (470–800)	800 (288–2525)
	Cyst fluid appearance Clear Opaque	15 (71%) 6 (29%)	8 (73%) 3 (27%)	6 (67%) 3 (33%)
	Cyst location (segments) Right hepatic lobe (segment 5–8) Left hepatic lobe (segment 2–4)	13 (62%) 8 (38%)	6 (55%) 5 (45%)	7 (70%) 3 (30%)
	Blood values Haemoglobin, mmol/L White blood cell count, 10⁹/L Total protein, g/L Creatinine, μmol/L eGFR, mL/min/1.73 m²	8.3 (7.5–8.7) 6.0 (5.0–7.0) 73.0 (71.0–76.0) 68.0 (61.0–77.9) 87.5 (68.8 – ≥90)	8.5 (7.5–8.8) 5.6 (4.3–7.4) 73.0 (71.5–75.5) 66.0 (57.8–69.8) ≥90 (81 – ≥90)	8.0 (7.4–8.8) 6.2 (5.4–6.7) 73.5 (70.8–77.3) 76.5 (64.0–81.3) 80 (64 – ≥90)
	Cyst fluid values Erythrocytes, 10⁹/L White blood cell count, 10⁹/L Protein, g/L pH	1.0 (0.0–9.0) 0.0 (0.0–0.5) 9.7 (5.0–22.6) 7.6 (7.5–7.7)	0.5 (0.0–11.0) 0.1 (0.0–4.4) 9.7 (4.8–22.0) 7.7 (7.6–7.7)	2.0 (0.0–54.5) 0.0 (0.0–0.6) 10.5 (5.0–28.7) 7.6 (7.5–7.7)
	ADPLD, autosomal-dominant polycystic liver disease; ADPKD, autosomal-dominant polycystic kidney disease; BMI, body mass index; CKD, chronic kidney disease
Results		Cyst-fluid-to-plasma concentration ratio (%)	Median (IQR)
	Ciprofloxacin	4.2%	(1.6%–8.9%)
	Piperacillin	0.3%	(0.0%–1.3%)
	Tazobactam	0.2%	(0.0%–1.3%)
	Trimethoprim	12.2%	(6.3%–16.1%)
	Sulfamethoxazole	0.4%	(0.2%–3.8%)
	Doxycycline	1.6%	(0.9%–2.3%)
Adverse Events	There were no adverse events related to the administration of the investigational products. There were no severe adverse events during the study.
Study Author Conclusions	Trimethoprim and ciprofloxacin have the highest penetration ratios amongst antibiotics tested. Liver cyst penetration varies widely between drugs after a single IV dose.
Critique	The study's strength lies in its controlled setting and randomized design, which minimizes biases. However, the single time point for drainage limits comprehensive pharmacokinetic analysis. The small sample size and single-dose design may not fully reflect clinical settings, and the lack of unbound drug concentration measurement is a limitation. Future studies should consider multiple doses and time points for a more complete understanding of drug penetration dynamics.

Table 3 References:
[6] Bernts LHP, Brüggemann RJM, Jansen AME, et al. Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial. J Antimicrob Chemother. 2025;80(1):182-191. doi:10.1093/jac/dkae394

First Simple Hepatic Cysts Case Report of Percutaneous Drainage and Sclerosis with Doxycycline
Design	Case report
Case presentation	A 71-year-old woman with hypertension and insulin-dependent diabetes mellitus presented with a 3-month history of progressively worsening right upper quadrant abdominal pain, accompanied by intermittent nausea, vomiting, and increased abdominal girth. Physical examination demonstrated hepatomegaly and right upper quadrant tenderness, while laboratory studies, including liver function tests, were within normal limits. Computed tomography and ultrasound identified multiple simple hepatic cysts, with the largest measuring 15.5 × 13.5 cm in the right hepatic lobe. Ultrasound-guided percutaneous cystography confirmed no communication with the biliary tree. The largest cyst was treated with ultrasound-guided percutaneous drainage, during which 1,350 mL of cyst fluid was aspirated. Doxycycline 1,500 mg diluted in 300 mL of normal saline was then instilled into the cyst cavity through the catheter. The catheter was clamped, and the patient was repositioned several times over 30 minutes to maximize contact of the sclerosant with the cyst wall. The doxycycline solution was subsequently drained, and the catheter was removed. No procedure-related complications occurred, and the patient remained pain-free at 7-month follow-up.
Study Author Conclusions	We have described the first successful use of doxycycline in the treatment of simple hepatic cysts. This compound appears to be safer than using 95% ethanol. Further studies are needed to determine the optimum volume and contact time of this agent.

Table 4 References:
[7] Tokunaga K, Teplick SK, Banerjee B. Simple hepatic cysts. First case report of percutaneous drainage and sclerosis with doxycycline, with a review of literature. Dig Dis Sci. 1994;39(1):209-214. doi:10.1007/BF02090085